A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
To determine the recommended Phase 2 dose of SAR405838 / pimasertib combination therapy in
patients with solid tumors.
To assess the anti-tumor activities of SAR405838 / pimasertib in patients with solid tumors.
Secondary Objectives:
To characterize the pharmacokinetic profile of SAR405838 and pimasertib.
To evaluate the pharmacodynamic effect of the SAR405838 and pimasertib.
To characterize genetic status in tumor tissue and circulating tumor DNA.